Diagnostic impact of high serum midkine level in patients with gastric cancer

We evaluated the diagnostic impact of serum midkine (s‐MK) levels in patients with gastric cancer using a monoclonal antibody enzyme‐linked immunosorbent assay system (ELISA) to detect s‐MK levels.

[1]  T. Nemoto,et al.  Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma , 2018, Esophagus.

[2]  T. Nemoto,et al.  Diagnostic and Prognostic Impact of Serum p53 Antibody Titration in Colorectal Cancer , 2017 .

[3]  Xuan Jing,et al.  Diagnostic accuracy of ELISA for detecting serum Midkine in cancer patients , 2017, PloS one.

[4]  M. Metintaş,et al.  Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin , 2017, BMC Cancer.

[5]  Honghe Luo,et al.  Midkine is a serum and urinary biomarker for the detection and prognosis of non-small cell lung cancer , 2016, Oncotarget.

[6]  A. Shiotani,et al.  Serum midkine as a biomarker for malignancy, prognosis, and chemosensitivity in head and neck squamous cell carcinoma , 2016, Cancer medicine.

[7]  D. Jones.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases , 2014, British journal of pharmacology.

[8]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[9]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[10]  M. Tagawa,et al.  Impact of serum biomarkers on esophageal squamous cell carcinoma , 2012, Esophagus.

[11]  X. Yao,et al.  Detection of serum midkine levels in cancer patients using rabbit anti-human midkine monoclonal antibodies , 2011 .

[12]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[13]  T. Muramatsu,et al.  Serum midkine concentrations and gastric cancer , 2005, Cancer science.

[14]  H. Matsubara,et al.  Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma , 2003, Cancer science.

[15]  T. Aikou,et al.  Serum midkine levels are increased in patients with various types of carcinomas , 2000, British Journal of Cancer.

[16]  M. Matsuyama,et al.  Expression of midkine in the early stage of carcinogenesis in human colorectal cancer , 1999, British Journal of Cancer.

[17]  T. Muramatsu,et al.  Enzyme-linked immunoassay for midkine, and its application to evaluation of midkine levels in developing mouse brain and sera from patients with hepatocellular carcinomas. , 1996, Journal of biochemistry.

[18]  J. Hermans,et al.  Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients , 1995, The Lancet.